Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03482583 · ClinicalTrials.gov registry record · Phase 4

Tobacco Use Treatment in Cancer Patients

A Phase 4 study, sponsored by University of Florida.

Completed
Registry status
Phase 4
Development phase
90
Enrollment target

NCT03482583 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03482583, a Phase 4 study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 4
Development phase
90 participants
Enrollment target

Study Summary

Tobacco use among cancer survivors reduces the effectiveness of cancer treatments, increases the risk for additional primary cancers, and increases mortality. Implementation of tobacco treatment for cancer patients is challenging, but may be improved substantially with clinically-efficient and sustainable solutions to accurately identify tobacco users, direct them to evidence-based treatment, and provide demonstrable outcomes for stakeholders. At UF Health Cancer Center (UFHCC), patient access and utilization of tobacco use treatment are sub optimal. Further, UFHCC has a largely rural catchment area with a high burden of tobacco-related disease and mortality. To address this research-to-practice gap using a mixed-methods approach to assess the relevant contextual factors at UFHCC and evaluate the feasibility of implementing a multi-level intervention to increase tobacco treatment utilization and improve health outcomes. This study uses a mixed methods approach and will inform the design of a pragmatic clinical trial to improve the delivery of tobacco use treatment services to cancer patients. Guided by a conceptual model that emphasizes patient, provider, and organizational characteristics, the study team will identify factors that influence the implementation process at the UFHCC. The ultimate goal of the proposed research is to provide new knowledge to facilitate the widespread adoption, implementation, and dissemination and sustained utilization of evidence-based tobacco use treatments in cancer care settings.

Interventions

  • DRUG Nicotine Replacement Therapy
  • OTHER Referral to AHEC/Quitline

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2018-05-14
Est. Completion 2019-12-31
Phase Phase 4

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT03482583

The ClinicalTrials.gov registry entry for NCT03482583 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Nicotine Replacement Therapy is the first listed.

NCT03482583 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03482583 about?

NCT03482583 is a clinical study titled "Tobacco Use Treatment in Cancer Patients". Tobacco use among cancer survivors reduces the effectiveness of cancer treatments, increases the risk for additional primary cancers, and increases mortality. Implementation of tobacco treatment for cancer patients is challenging, but may be improved substantially with clinically-efficient and susta...

What is the current status of trial NCT03482583?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2018-05-14. Estimated completion is 2019-12-31.

What interventions are being tested in trial NCT03482583?

The interventions under investigation include: Nicotine Replacement Therapy (DRUG), Referral to AHEC/Quitline (OTHER).

Who is sponsoring clinical trial NCT03482583?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.